1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Editorial
You have full text access to this OnlineOpen article
Molecular ablation of transforming growth factor β signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosis
Article first published online: 30 JUL 2008
DOI: 10.1002/art.23634
Copyright © 2008 by the American College of Rheumatology
Additional Information
How to Cite
Rosenbloom, J. and Jiménez, S. A. (2008), Molecular ablation of transforming growth factor β signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosis. Arthritis & Rheumatism, 58: 2219–2224. doi: 10.1002/art.23634
Publication History
- Issue published online: 30 JUL 2008
- Article first published online: 30 JUL 2008
- Manuscript Accepted: 18 APR 2008
- Manuscript Received: 26 MAR 2008
Funded by
- NIH. Grant Number: R01-AR-019616
REFERENCES
- 1, . Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557–67.
- 2, . Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37–50.
- 3, . Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 2005; 11: 3943–71.
- 4, , . Mechanisms of liver fibrosis [review]. Clin Chim Acta 2006; 364: 33–60.
- 5. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213–7.
- 6, , , , , . Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35: 238–49.
- 7, , . Role of transforming growth factor β in human disease. N Engl J Med 2000; 342: 1350–8.
- 8, . TGFβ-SMAD signal transduction: molecular specificity and functional flexibility [review]. Nat Rev Mol Cell Biol 2007; 8: 970–82.
- 9, . The logic of TGFβ signaling [review]. FEBS Lett 2006; 580: 2811–20.
- 10, , . Smad transcription factors. Genes Dev 2005; 19: 2783–810.
- 11, . TGF-β signaling: a tale of two responses [review]. J Cell Biochem 2007; 102: 593–608.Direct Link:
- 12, . Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 2003; 425: 577–84.
- 13, . Transforming growth factor β activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 2006; 281: 27846–54.
- 14, , , , , , et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002; 99: 381–3.
- 15, , , , , , et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002; 117: 360–7.
- 16, , , , , . Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. Int J Hematol 2002; 76: 349–53.
- 17, , , , , , et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308–16.
- 18, , , , , , et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288: G907–13.
- 19, , , . Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 1–11.
- 20, , , , , , et al. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. Cardiovasc Res 2008. E-pub ahead of print.
- 21, , , , , , et al. Novel role of C-abl tyrosine kinase in profibrotic TGF-β responses: selective modulation by the anticancer drug imatinib methylate (gleevec) [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S776.
- 22, , , , , , et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311–22.Direct Link:
- 23, , , , , , et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008; 216: 109–17. E-pub ahead of print.
- 24, , , , , , et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008; 58: 2528–37.Direct Link:
- 25, , , , , , et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008; 58: 2549–52.Direct Link:
- 26, , , , , , et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281–5.
- 27, , , , . Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008; 58: 2538–42.Direct Link:
- 28, . Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543–8.Direct Link:
- 29. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel? [editorial]. Arthritis Rheum 2007; 56: 9–12.Direct Link: